The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS
暂无分享,去创建一个
F. Barkhof | M. Rovaris | M. Filippi | C. Pozzilli | L. Kappos | C. Polman | T. Yousry | G. Comi | M. Inglese | J. V. van Waesberghe | D. Hahn | A. Thompson | D.H. Miller | K. Wagner | K. Beckmann | D. Miller | J. Waesberghe | D. Miller | L. Kappos | J.H.T.M. van Waesberghe | D. Miller | J. V. Waesberghe
[1] Simon K Warfield,et al. Diffusion Tensor Magnetic Resonance Imaging in Multiple Sclerosis , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[2] M Filippi,et al. Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: Consensus report of the White Matter Study Group , 2002, Journal of magnetic resonance imaging : JMRI.
[3] Massimo Filippi,et al. MRI techniques to monitor MS evolution: The present and the future , 2002, Neurology.
[4] F. Barkhof,et al. The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MS , 2001, Neurology.
[5] E. Cho,et al. Immunopathology of secondary‐progressive multiple sclerosis , 2001, Annals of neurology.
[6] A. Thompson,et al. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. , 2001, Brain : a journal of neurology.
[7] D. Li,et al. Randomized controlled trial of interferon-beta-1a in secondary progressive MS , 2001, Neurology.
[8] Randomized controlled trial of interferon- beta-1a in secondary progressive MS , 2001, Neurology.
[9] M. Horsfield,et al. Scan-rescan variation of measures derived from brain magnetization transfer ratio histograms obtained in healthy volunteers by use of a semi-interleaved magnetization transfer sequence. , 2001, AJNR. American journal of neuroradiology.
[10] F. Barkhof,et al. Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy , 2001, Journal of the Neurological Sciences.
[11] J L Ostuni,et al. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis , 2001, Multiple sclerosis.
[12] D. Goldblatt. A messy necessary end , 2001, Neurology.
[13] P. C. de Freitas Mathias,et al. Insulin Secretion and Acetylcholinesterase Activity in Monosodium L-Glutamate-Induced Obese Mice , 2001, Hormone Research in Paediatrics.
[14] M Rovaris,et al. Whole brain volume changes in patients with progressive MS treated with cladribine , 2000, Neurology.
[15] G. Comi,et al. Magnetization transfer imaging to monitor the evolution of MS , 2000, Neurology.
[16] S. Majumdar,et al. Magnetization transfer ratio in new MS lesions before and during therapy with IFNβ-1a , 2000, Neurology.
[17] M Filippi,et al. A magnetization transfer histogram study of normal-appearing brain tissue in MS , 2000, Neurology.
[18] M Cercignani,et al. Reproducibility of magnetization transfer ratio histogram-derived measures of the brain in healthy volunteers. , 2000, AJNR. American journal of neuroradiology.
[19] A. Thompson,et al. The effect of interferon beta-1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis , 2000 .
[20] G. Barker,et al. Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial , 1999 .
[21] F. Barkhof,et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.
[22] G. Barker,et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H , 1999, Neurology.
[23] A. Compston,et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis , 1999, Annals of neurology.
[24] D. Paty,et al. Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis , 1999 .
[25] M Filippi,et al. Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. , 1999, AJNR. American journal of neuroradiology.
[26] M Filippi,et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI , 1999, Neurology.
[27] G J Barker,et al. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. , 1999, Annals of neurology.
[28] Ludwig Kappos,et al. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.
[29] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[30] J. Duyn,et al. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. , 1998, AJNR. American journal of neuroradiology.
[31] J K Udupa,et al. Correlation of volumetric magnetization transfer imaging with clinical data in MS , 1998, Neurology.
[32] M Rovaris,et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis , 1998, Neurology.
[33] P M Matthews,et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.
[34] P. Batchelor,et al. International Society for Magnetic Resonance in Medicine , 1997 .
[35] D L Hill,et al. Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. , 1997, Medical physics.
[36] F. Barkhof,et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis , 1996, Neurology.
[37] P M Matthews,et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. , 1996, Brain : a journal of neurology.
[38] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[39] Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. , 1995, Neurology.
[40] G. Barker,et al. Correlation of magnetization transfer ration with clinical disability in multiple sclerosis , 1994, Annals of neurology.
[41] R I Grossman,et al. Magnetization transfer in multiple sclerosis , 1994, Annals of neurology.
[42] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[43] Stephen M. Rao,et al. Cognitive dysfunction in multiple sclerosis. , 1991, Neurology.
[44] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.